Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Entasis Therapeutics Holdings stock price, quote, forecast and news

ETTX
US2936141033
A2N4R0

Price

2.19
Today +/-
+0
Today %
+0 %
P

Entasis Therapeutics Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Entasis Therapeutics Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Entasis Therapeutics Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Entasis Therapeutics Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Entasis Therapeutics Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Entasis Therapeutics Holdings Stock Price History

DateEntasis Therapeutics Holdings Price
7/11/20222.19 undefined
7/8/20222.19 undefined

Entasis Therapeutics Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Entasis Therapeutics Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Entasis Therapeutics Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Entasis Therapeutics Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Entasis Therapeutics Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Entasis Therapeutics Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Entasis Therapeutics Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Entasis Therapeutics Holdings’s growth potential.

Entasis Therapeutics Holdings Revenue, EBIT and net profit per share

DateEntasis Therapeutics Holdings RevenueEntasis Therapeutics Holdings EBITEntasis Therapeutics Holdings Net Income
2026e201.98 M undefined-53.23 M undefined-46.56 M undefined
2025e80.79 M undefined-43.41 M undefined-37.32 M undefined
2024e32.96 M undefined-36.11 M undefined-30.5 M undefined
2023e7.99 M undefined-62.27 M undefined-56.13 M undefined
2022e0 undefined-64.34 M undefined-58.41 M undefined
20210 undefined-52.32 M undefined-47.14 M undefined
20200 undefined-54.23 M undefined-50.5 M undefined
20197 M undefined-46.94 M undefined-43.85 M undefined
20185 M undefined-38.21 M undefined-32.95 M undefined
20170 undefined-31.34 M undefined-29.92 M undefined
20160 undefined-19.1 M undefined-19.1 M undefined

Entasis Therapeutics Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2016201720182019202020212022e2023e2024e2025e2026e
005700073280201
---40.00----357.14150.00151.25
-----------
00000000000
-19-31-38-46-54-52-64-62-36-43-53
---760.00-657.14----885.71-112.50-53.75-26.37
-19-29-32-43-50-47-58-56-30-37-46
-52.6310.3434.3816.28-6.0023.40-3.45-46.4323.3324.32
13.0713.0713.0713.1624.0643.3400000
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Entasis Therapeutics Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Entasis Therapeutics Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201620172018201920202021
           
26.2655.185.094153.2532.31
00.721.711.231.891.26
23000000
000000
0.150.51.996.7856.25
26.6456.3288.7949.0160.1439.82
0.360.650.421.971.360.8
000000
000000
000000
000000
0.061.830.060.060.060.3
0.422.480.482.031.421.1
27.0658.889.2751.0461.5640.92
           
48.42104.710.010.010.040.05
0.91.38172.99176.1236.71262.76
-27.25-57.17-90.11-133.96-184.46-231.6
00-0.010031.21
000000
22.0748.9282.8842.1552.2962.42
0.92.221.371.30.661.18
3.447.624.856.257.918.53
62000000
000000
000000
4.969.846.227.558.579.71
000000
000000
0.030.040.181.320.70
0.030.040.181.320.70
4.999.886.48.879.279.71
27.0658.889.2851.0261.5672.13
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Entasis Therapeutics Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Entasis Therapeutics Holdings's financial health and stability.

Assets

Entasis Therapeutics Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Entasis Therapeutics Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Entasis Therapeutics Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Entasis Therapeutics Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201620172018201920202021
-19-29-32-43-50-47
000000
000000
22-4-220
001124
000000
000000
-15-27-35-44-45-42
000000
00-3611240
00-3511250
000000
000000
4256005722
42566605722
0066000
000000
2628-5-3337-20
000000
000000

Entasis Therapeutics Holdings stock margins

The Entasis Therapeutics Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Entasis Therapeutics Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Entasis Therapeutics Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Entasis Therapeutics Holdings's sales revenue. A higher gross margin percentage indicates that the Entasis Therapeutics Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Entasis Therapeutics Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Entasis Therapeutics Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Entasis Therapeutics Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Entasis Therapeutics Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Entasis Therapeutics Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Entasis Therapeutics Holdings Margin History

Entasis Therapeutics Holdings Gross marginEntasis Therapeutics Holdings Profit marginEntasis Therapeutics Holdings EBIT marginEntasis Therapeutics Holdings Profit margin
2026e0 %-26.35 %-23.05 %
2025e0 %-53.73 %-46.19 %
2024e0 %-109.55 %-92.54 %
2023e0 %-778.97 %-702.15 %
2022e0 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %-670.57 %-626.43 %
20180 %-764.2 %-659 %
20170 %0 %0 %
20160 %0 %0 %

Entasis Therapeutics Holdings Stock Sales Revenue, EBIT, Earnings per Share

The Entasis Therapeutics Holdings earnings per share therefore indicates how much revenue Entasis Therapeutics Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Entasis Therapeutics Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Entasis Therapeutics Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Entasis Therapeutics Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Entasis Therapeutics Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Entasis Therapeutics Holdings Revenue, EBIT and net profit per share

DateEntasis Therapeutics Holdings Sales per ShareEntasis Therapeutics Holdings EBIT per shareEntasis Therapeutics Holdings Earnings per Share
2026e4.22 undefined0 undefined-0.97 undefined
2025e1.69 undefined0 undefined-0.78 undefined
2024e0.69 undefined0 undefined-0.64 undefined
2023e0.17 undefined0 undefined-1.17 undefined
2022e0 undefined0 undefined-1.22 undefined
20210 undefined-1.21 undefined-1.09 undefined
20200 undefined-2.25 undefined-2.1 undefined
20190.53 undefined-3.57 undefined-3.33 undefined
20180.38 undefined-2.92 undefined-2.52 undefined
20170 undefined-2.4 undefined-2.29 undefined
20160 undefined-1.46 undefined-1.46 undefined

Entasis Therapeutics Holdings business model

Entasis Therapeutics Holdings Inc is a biopharmaceutical company focused on the development and commercialization of novel antibiotics to combat infectious diseases. The company was founded in 2015 by a team of experienced executives, researchers, and academics in the biotechnology industry specializing in the field of infectious diseases. Entasis's business model is based on the discovery and development of novel antibiotics effective against multi-drug resistant bacteria. The company utilizes its own technology platform to identify drug candidates based on the specific needs of patients and global health threats. Entasis aims to develop innovative therapies to solve global health problems and save lives. The company is focused on the development of two main categories of drug candidates: antibiotics against gram-negative bacteria and innovative combination therapies to combat antibiotic resistance. Entasis has developed a pipeline of high-potential antibiotic candidates, including ETX2514, a next-generation antibiotic to combat beta-lactam resistance, and recently SUL-digenem, a combination of one of the most commonly used antibiotics, sulbactam, and their newly developed antibiotic durlobactam. The company also emphasizes strategic partnerships, such as its current partnership with GARDP, a joint venture between the World Health Organization and the Drugs for Neglected Diseases Initiative. Entasis has also developed a range of products to combat infectious diseases. One of these products is the antibiotic zoliflodacin, used for the treatment of sexually transmitted diseases such as gonorrhea. It is in the late stage of clinical development and could soon enter the market. Another product is sulbactam-durlobactam, used for the treatment of infections caused by gram-negative bacteria, currently in clinical development. The company has a strong presence in the academic world and actively builds partnerships with leading institutions to support its research and development efforts. It collaborates with universities and research institutes in the USA and Europe to develop new drug candidates and therapies with the potential to revolutionize the treatment of infectious diseases. Entasis Therapeutics Holdings Inc is an innovative biopharmaceutical company that improves global health through the development of novel antibiotics and combination therapies. The company has an impressive pipeline of antibiotic candidates targeting infections caused by multi-drug resistant bacteria. Through collaborative agreements and the latest scientific advancements, Entasis hopes to develop even more life-saving medications in the future. Entasis Therapeutics Holdings is one of the most popular companies on Eulerpool.com.

Entasis Therapeutics Holdings SWOT Analysis

Strengths

Entasis Therapeutics Holdings Inc has a strong focus on innovative research and development, leading to the discovery and development of new drugs to combat bacterial infections. The company's dedicated R&D team utilizes advanced technologies and cutting-edge methodologies to design novel antibiotics, providing a competitive advantage in the market.

Entasis Therapeutics boasts a robust intellectual property portfolio, consisting of patents and proprietary technologies. This provides a significant barrier to entry for competitors, protecting the company's innovative products and ensuring potential revenue streams through licensing and partnerships.

The company is led by an experienced management team with deep expertise in the pharmaceutical industry. This team possesses a strong track record of successfully navigating drug development processes, securing funding, and executing strategic partnerships, which enhances Entasis Therapeutics' ability to bring products to market.

Weaknesses

As a biopharmaceutical company, Entasis Therapeutics heavily relies on the success of its research and development efforts. The failure to identify viable drug candidates or successfully complete clinical trials could result in significant setbacks, impacting the company's financial stability and reputation.

Currently, Entasis Therapeutics' product portfolio is limited, with a focus on developing antibiotics for multi-drug resistant bacterial infections. This narrow focus increases the company's vulnerability to shifts in market demand, potential regulatory hurdles, and intensifying competition from larger pharmaceutical companies.

Opportunities

The global demand for effective anti-infective drugs continues to rise due to the increasing prevalence of bacterial infections and the emergence of drug-resistant strains. Entasis Therapeutics is well-positioned to capitalize on this opportunity by leveraging its pipeline of antibiotics developed to address these urgent medical needs.

The biopharmaceutical industry frequently engages in strategic partnerships and collaborations to share resources, expertise, and financial risks. Entasis Therapeutics can explore partnerships with larger pharmaceutical companies, academic institutions, or government agencies to accelerate drug development, increase market reach, and access additional funding.

Threats

The pharmaceutical industry is subject to strict regulations and rigorous approval processes worldwide. Entasis Therapeutics faces the risk of delays or failure in obtaining necessary regulatory approvals for its drugs, which could significantly impede product commercialization and limit revenue generation.

The market for antibiotics and anti-infective drugs is highly competitive, with numerous established pharma companies and emerging biotech firms vying for market share. Entasis Therapeutics must navigate intense competition, pricing pressures, and the need to differentiate its products to attract physicians, payers, and patients in a crowded market.

Entasis Therapeutics Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Entasis Therapeutics Holdings historical P/E ratio, EBIT, and P/S ratio.

Entasis Therapeutics Holdings shares outstanding

The number of shares was Entasis Therapeutics Holdings in 2023 — This indicates how many shares 43.34 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Entasis Therapeutics Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Entasis Therapeutics Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Entasis Therapeutics Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Entasis Therapeutics Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Entasis Therapeutics Holdings.

Entasis Therapeutics Holdings list of shareholders

%
Name
Stocks
Change
Date
59.92246 % Innoviva Inc28,672,89703/15/2022
4.52425 % AstraZeneca PLC2,164,85504/1/2021
2.13322 % TPG Capital, L.P.1,020,74801/12/2022
1.23428 % Eventide Asset Management, LLC590,602012/31/2021
0.94034 % The Vanguard Group, Inc.449,95523,72012/31/2021
0.67575 % Renaissance Technologies LLC323,34510,80012/31/2021
0.56059 % Two Sigma Investments, LP268,242-146,98812/31/2021
0.39623 % Tommasi (Ruben Ph.D.)189,596125,0001/18/2022
0.37842 % Perros (Manoussos)181,072125,0001/18/2022
0.35020 % Gutch (Michael Ph.D.)167,572125,0001/18/2022
1
2
3
4
5
...
9

Most common questions regarding Entasis Therapeutics Holdings

What values and corporate philosophy does Entasis Therapeutics Holdings represent?

Entasis Therapeutics Holdings Inc represents a commitment to developing novel antibacterial therapies to combat multidrug-resistant bacteria. Their corporate philosophy centers around scientific innovation and collaboration to address critical unmet medical needs. Entasis Therapeutics is dedicated to improving patient outcomes by employing a multi-faceted approach that encompasses rigorous research, development, and commercialization of potential life-saving treatments. With a focus on sustainability and integrity, Entasis Therapeutics aims to provide effective solutions to combat the growing threat of antibiotic resistance.

In which countries and regions is Entasis Therapeutics Holdings primarily present?

Entasis Therapeutics Holdings Inc is primarily present in the United States.

What significant milestones has the company Entasis Therapeutics Holdings achieved?

Entasis Therapeutics Holdings Inc has achieved several significant milestones. The company successfully conducted Phase 1 clinical trials for its leading product candidate, ETX2514SUL, which showed promising results in combating drug-resistant bacterial infections. Entasis Therapeutics also advanced its novel compounds in various stages of development, aiming to address unmet medical needs. Additionally, the company forged strategic collaborations, such as a partnership with Zai Lab, to further enhance its drug discovery and development efforts. Entasis Therapeutics continues to focus on advancing innovative therapies to combat infectious diseases and improve patient outcomes.

What is the history and background of the company Entasis Therapeutics Holdings?

Entasis Therapeutics Holdings Inc is a leading biopharmaceutical company focused on developing innovative antimicrobial therapies to combat infectious diseases. Founded in 2015, the company is dedicated to addressing the global threat of antibiotic resistance. Entasis Therapeutics leverages its seasoned team of experts to discover and develop novel small molecule drugs that target serious bacterial infections. With a strong commitment to patient health, the company utilizes cutting-edge technologies and approaches to deliver effective and safe treatments. Entasis Therapeutics is constantly evolving its pipeline to meet the unmet medical needs of patients worldwide, solidifying its position as a trusted player in the fight against infectious diseases.

Who are the main competitors of Entasis Therapeutics Holdings in the market?

The main competitors of Entasis Therapeutics Holdings Inc in the market include pharmaceutical companies such as Pfizer Inc., Merck & Co., Inc., and AstraZeneca PLC. These companies operate in the same industry and compete in the development and commercialization of innovative therapeutics and drugs. Entasis Therapeutics Holdings Inc faces competition in the areas of research, clinical trials, marketing, and market share. The company continually strives to differentiate itself through its unique product offerings, technology, and scientific advancements to gain a competitive edge in the market.

In which industries is Entasis Therapeutics Holdings primarily active?

Entasis Therapeutics Holdings Inc is primarily active in the pharmaceutical industry.

What is the business model of Entasis Therapeutics Holdings?

The business model of Entasis Therapeutics Holdings Inc is focused on developing novel antibacterial therapies to address life-threatening multidrug-resistant infections. By leveraging its expertise in infectious diseases, Entasis aims to discover and develop innovative treatments that combat antibiotic-resistant bacteria. The company employs a target-based approach, utilizing its proprietary technology platforms to identify and optimize potential drug candidates. Entasis Therapeutics also seeks strategic collaborations and partnerships to advance its research and development efforts. As a leading pharmaceutical firm, Entasis Therapeutics Holdings Inc is committed to addressing the urgent need for effective therapies against antimicrobial resistance.

What is the P/E ratio of Entasis Therapeutics Holdings 2024?

The Entasis Therapeutics Holdings P/E ratio is -3.11.

What is the P/S ratio of Entasis Therapeutics Holdings 2024?

The Entasis Therapeutics Holdings P/S ratio is 2.88.

What is the AlleAktien quality score of Entasis Therapeutics Holdings?

The AlleAktien quality score for Entasis Therapeutics Holdings is 2/10.

What is the revenue of Entasis Therapeutics Holdings 2024?

The expected Entasis Therapeutics Holdings revenue is 32.96 M USD.

How high is the profit of Entasis Therapeutics Holdings 2024?

The expected Entasis Therapeutics Holdings profit is -30.5 M USD.

What is the business model of Entasis Therapeutics Holdings

Entasis Therapeutics Holdings Inc is an innovative biopharmaceutical company specializing in the development of new medications for the treatment of infectious diseases. The company offers its products and services worldwide and is headquartered in Waltham, Massachusetts. Entasis Therapeutics' business model is based on the development of novel medications for unmet medical needs. The company utilizes its own platform technology to develop innovative therapeutics targeting antibiotic-resistant bacteria for the treatment of bacterial infections. Entasis collaborates closely with physicians, biologists, and other medical science professionals to develop improved treatments for patients with severe infections. Entasis offers several products for the treatment of bacterial infections. For example, the company is developing PATG-1177, a promising new therapy for the treatment of Pseudomonas infections in individuals with cystic fibrosis. It has also developed ETX0282CPDP, a new antibiotic for the treatment of infections caused by Enterobacteriaceae. Another product from Entasis is an oral antibiotic called SUL-DUR, which is approved for the treatment of urinary tract infections in women. Entasis also collaborates closely with other companies to support its research and development efforts. For instance, the company has partnered with global pharmaceutical firm GSK to jointly work on new therapeutics for the treatment of bacterial infections. Additionally, Entasis recently entered into a partnership with South Korean company GtreeBNT to develop a new class of antibiotics. Entasis is divided into three main business segments: therapeutics, platform technologies, and chemical services. In the therapeutics segment, the company develops and produces innovative medications for the treatment of bacterial infections. In the platform technology segment, Entasis utilizes its platform to identify new drug candidates targeting antibiotic-resistant bacteria. In the chemical services segment, Entasis also offers customized synthetic chemistry services and research and development services for companies advancing novel drug development. In summary, Entasis Therapeutics' business model focuses on the development of innovative medications for the treatment of severe bacterial infections. Through the utilization of its own platform technologies and collaborations with other companies, Entasis is able to develop and bring new therapeutics to market. With its various business segments and products, Entasis is a leading company that continues to expand and advance its industry leadership in the biopharmaceutical industry.

What is the Entasis Therapeutics Holdings dividend?

Entasis Therapeutics Holdings pays a dividend of 0 USD distributed over payouts per year.

How often does Entasis Therapeutics Holdings pay dividends?

The dividend cannot currently be calculated for Entasis Therapeutics Holdings or the company does not pay out a dividend.

What is the Entasis Therapeutics Holdings ISIN?

The ISIN of Entasis Therapeutics Holdings is US2936141033.

What is the Entasis Therapeutics Holdings WKN?

The WKN of Entasis Therapeutics Holdings is A2N4R0.

What is the Entasis Therapeutics Holdings ticker?

The ticker of Entasis Therapeutics Holdings is ETTX.

How much dividend does Entasis Therapeutics Holdings pay?

Over the past 12 months, Entasis Therapeutics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Entasis Therapeutics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Entasis Therapeutics Holdings?

The current dividend yield of Entasis Therapeutics Holdings is .

When does Entasis Therapeutics Holdings pay dividends?

Entasis Therapeutics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Entasis Therapeutics Holdings?

Entasis Therapeutics Holdings paid dividends every year for the past 0 years.

What is the dividend of Entasis Therapeutics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Entasis Therapeutics Holdings located?

Entasis Therapeutics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Entasis Therapeutics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Entasis Therapeutics Holdings from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Entasis Therapeutics Holdings pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Entasis Therapeutics Holdings in the year 2023?

In the year 2023, Entasis Therapeutics Holdings distributed 0 USD as dividends.

In which currency does Entasis Therapeutics Holdings pay out the dividend?

The dividends of Entasis Therapeutics Holdings are distributed in USD.

All fundamentals about Entasis Therapeutics Holdings

Our stock analysis for Entasis Therapeutics Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Entasis Therapeutics Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.